|
|
Exchange: |
Nasdaq National Market |
Security
Type: |
Common |
Shares
Out: |
85,817,000 |
Market
Cap: |
232.56(M) |
Last
Volume: |
0 |
Avg
Vol: |
0 |
52
Week Range: |
$1.69 - $3.12 |
|
Level
I Sector: |
N/A |
Level
II Sector: |
N/A |
Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile Arbutus Biopharma is a clinical-stage biopharmaceutical company utilizing its virology expertise to develop therapeutics that target specific viral diseases. Co.'s focus areas include Hepatitis B virus (HBV), SARS-CoV-2 and other coronaviruses. Co.'s product pipeline consists of the following programs: GalNAc RNAi, which is a subcutaneously-delivered RNA interference therapeutic targeted to hepatocytes; Oral Capsid Inhibitor, which is a capsid inhibitor; Oral PD-L1 Inhibitor, which is an oral PD-L1 inhibitor that has the potential to reawaken patients' HBV-specific immune response; and Oral HBV RNA Destabilizer, which is is Co.'s oral HBV specific RNA destabilizer.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
0 |
0 |
Total Buy Value |
$0 |
$0 |
$0 |
$0 |
Total People Bought |
0 |
0 |
0 |
0 |
Total Buy Transactions |
0 |
0 |
0 |
0 |
Total Shares Sold |
0 |
34,097 |
34,097 |
34,097 |
Total Sell Value |
$0 |
$78,849 |
$78,849 |
$78,849 |
Total People Sold |
0 |
4 |
4 |
4 |
Total Sell Transactions |
0 |
4 |
4 |
4 |
End Date |
2024-02-04 |
2023-11-03 |
2023-05-05 |
2022-05-05 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Sofia Michael J. |
Chief Scientific Officer |
|
2024-02-02 |
4 |
AS |
$2.31 |
$23,083 |
D/D |
(9,982) |
1,485,121 |
|
15% |
|
Hastings David C |
Chief Financial Officer |
|
2024-02-02 |
4 |
AS |
$2.31 |
$22,184 |
D/D |
(9,593) |
181,907 |
|
15% |
|
Mcelhaugh Michael J. |
Interim President & CEO |
|
2024-02-02 |
4 |
AS |
$2.31 |
$23,504 |
D/D |
(10,164) |
1,504,793 |
|
15% |
|
Sims Karen |
Chief Medical Officer |
|
2024-02-02 |
4 |
AS |
$2.31 |
$10,078 |
D/D |
(4,358) |
125,542 |
|
15% |
|
Sofia Michael J. |
Chief Scientific Officer |
|
2024-02-01 |
4 |
A |
$0.00 |
$0 |
D/D |
109,500 |
1,495,103 |
|
- |
|
Naftzger J. Christopher |
General Counsel and CCO |
|
2024-02-01 |
4 |
A |
$0.00 |
$0 |
D/D |
95,100 |
95,100 |
|
- |
|
Hastings David C |
Chief Financial Officer |
|
2024-02-01 |
4 |
A |
$0.00 |
$0 |
D/D |
112,500 |
191,500 |
|
- |
|
Mcelhaugh Michael J. |
Interim President & CEO |
|
2024-02-01 |
4 |
A |
$0.00 |
$0 |
D/D |
123,800 |
1,514,957 |
|
- |
|
Sims Karen |
Chief Medical Officer |
|
2024-02-01 |
4 |
A |
$0.00 |
$0 |
D/D |
101,000 |
129,900 |
|
- |
|
Sims Karen |
Chief Medical OfficerOfficer |
|
2023-07-10 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
28,900 |
|
-17% |
|
Hastings David C |
Chief Financial Officer |
|
2023-02-01 |
4 |
A |
$0.00 |
$0 |
D/D |
79,000 |
79,000 |
|
- |
|
Collier William H. |
President and CEO |
|
2023-02-01 |
4 |
A |
$0.00 |
$0 |
D/D |
216,500 |
216,500 |
|
- |
|
Howard Elizabeth |
EVP, GC, Compliance |
|
2023-02-01 |
4 |
A |
$0.00 |
$0 |
D/D |
69,700 |
86,024 |
|
- |
|
Mcelhaugh Michael J. |
Chief Business Officer |
|
2023-02-01 |
4 |
A |
$0.00 |
$0 |
D/D |
83,700 |
1,391,157 |
|
- |
|
Sofia Michael J. |
Chief Scientific Officer |
|
2023-02-01 |
4 |
A |
$0.00 |
$0 |
D/D |
82,200 |
1,385,603 |
|
- |
|
Sofia Michael J. |
Chief Scientific Officer |
|
2021-12-01 |
4 |
AS |
$5.09 |
$1,018,000 |
D/D |
(200,000) |
1,303,403 |
|
-39% |
|
Roivant Sciences Ltd. |
10% Owner |
|
2021-10-18 |
4 |
A |
$0.00 |
$0 |
D/D |
22,833,922 |
38,847,462 |
|
- |
|
Mcelhaugh Michael J. |
Chief Business Officer |
|
2021-02-09 |
4 |
AS |
$5.00 |
$100,000 |
D/D |
(20,000) |
1,307,457 |
|
-30% |
|
Mcelhaugh Michael J. |
Chief Business Officer |
|
2020-12-14 |
4 |
AS |
$5.00 |
$200,032 |
D/D |
(40,000) |
1,327,457 |
|
-33% |
|
Mcelhaugh Michael J. |
Chief Business Officer |
|
2020-07-23 |
4 |
AS |
$5.01 |
$100,200 |
D/D |
(20,000) |
1,367,457 |
|
-36% |
|
Murray Mark J. |
Director |
|
2018-11-28 |
4 |
OE |
$1.35 |
$33,750 |
D/D |
25,000 |
341,396 |
|
- |
|
Sofia Michael J. |
Chief Scientific Officer |
|
2018-08-13 |
4/A |
S |
$9.51 |
$40,436 |
I/I |
(4,250) |
167,162 |
|
- |
|
Sofia Michael J. |
Chief Scientific Officer |
|
2018-08-13 |
4 |
S |
$9.51 |
$40,436 |
D/D |
(4,250) |
1,499,153 |
|
- |
|
Sofia Michael J. |
Chief Scientific Officer |
|
2018-07-11 |
4 |
AS |
$10.00 |
$100,000 |
D/D |
(10,000) |
1,503,403 |
|
- |
|
Sofia Michael J. |
Chief Scientific Officer |
|
2018-07-09 |
4 |
AS |
$8.91 |
$89,060 |
D/D |
(10,000) |
1,513,403 |
|
- |
|
60 Records found
|
|
Page 1 of 3 |
|
|